Pharma giant AstraZeneca struck a deal Saturday with Europe’s Inclusive Vaccines Alliance to supply up to 400 million doses of an experimental COVID-19 vaccine, as efforts to boost manufacturing capacity continue at pace.
The alliance, which was forged by Germany, France, Italy and the Netherlands to speed up production of a vaccine, is set to take delivery of the vaccine being tested by the University of Oxford by the end of 2020. The agreement with AstraZeneca also aims to make the vaccine available to other European countries that wish to take part.
The cost is expected to be offset by funding from the governments.
“This agreement will ensure that hundreds of millions of Europeans have access to Oxford University’s vaccine following approval,” AstraZeneca CEO Pascal Soriot said. “With our European supply chain due to begin production soon, we hope to make the vaccine available widely and rapidly.”
The agreement is the latest in a series to make the vaccine—even though it is not certain it will work. But so desperate is the need that scaling up of manufacturing continues despite the risk.
The Anglo-Swedish company recently completed similar agreements with Britain, the United States the Coalition for Epidemic Preparedness Innovations, and Gavi, the Vaccine Alliance for 700 million doses. A license also has been agreed with the Serum Institute of India for another 1 billion doses.
The vaccine was developed by Oxford University’s Jenner Institute, working with the Oxford Vaccine Group.
Testing of the experimental COVID-19 vaccine began in healthy volunteers in Britain in April with over 1,000 people aged 18 to 55. Another round with 10,000 volunteers began last month.
Other companies, including Moderna and Sanofi, are racing to develop and produce a vaccine against the new coronavirus, a step experts say will be crucial to allowing countries to ease their lockdowns and restrictions on public life.
Follow the latest news on the coronavirus (COVID-19) outbreak
© 2020 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed without permission.
AstraZeneca agrees to make COVID-19 vaccine for Europe (2020, June 13)
retrieved 13 June 2020
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no
part may be reproduced without the written permission. The content is provided for information purposes only.
- COVID case rates hit new high for England, study finds - April 7, 2022
- Govt’s focus on affordable healthcare ensured significant savings for poor, middle class: PM Modi - April 7, 2022
- SRL Diagnostics and Skye Air Mobility collaborate to transport pathology samples using drone logistics - April 6, 2022
- Healthineers sets up new production line of CT scanners in Bengaluru under PLI scheme - April 6, 2022
- Lupin inks licensing pact with Alvion to market drugs in Southeast Asia - April 6, 2022
- Yoga Mahotsav: Ayush Ministry to organise event to demonstrate common yoga on World Health Day - April 6, 2022
- LordsMed forays into the medtech space with launch of health ATMs ‘Lords Sehat’ - April 5, 2022
- ‘Friendly viruses’ can be the next big thing in the history of medical research and more - April 5, 2022
- No setback to Bharat Biotech even as WHO suspends Covaxin UN supply: Sources - April 4, 2022
- Govt panel recommends Serum’s Covovax dose for kids aged 12 and above - April 4, 2022